Primary |
Insulin-requiring Type Ii Diabetes Mellitus |
66.7% |
Type 1 Diabetes Mellitus |
33.3% |
|
Blood Glucose Decreased |
33.3% |
Myalgia |
33.3% |
Weight Decreased |
33.3% |
|
Secondary |
Product Used For Unknown Indication |
41.8% |
Diabetes Mellitus |
10.9% |
Angina Pectoris |
7.3% |
Cardiac Failure |
7.3% |
Type 1 Diabetes Mellitus |
7.3% |
Type 2 Diabetes Mellitus |
5.5% |
Diabetes Mellitus Insulin-dependent |
3.6% |
Gastrooesophageal Reflux Disease |
3.6% |
Hypokalaemia |
3.6% |
Lung Neoplasm Malignant |
3.6% |
Metastases To Central Nervous System |
3.6% |
Plasma Cell Myeloma |
1.8% |
|
Vomiting |
18.2% |
Blood Glucose Increased |
9.1% |
Haematoma |
9.1% |
Infarction |
9.1% |
Injection Site Haematoma |
9.1% |
Injection Site Urticaria |
9.1% |
Malaise |
9.1% |
Pain In Extremity |
9.1% |
Rash |
9.1% |
Urticaria |
9.1% |
|
Concomitant |
Type 2 Diabetes Mellitus |
43.3% |
Insulin-requiring Type 2 Diabetes Mellitus |
14.6% |
Chronic Myeloid Leukaemia |
4.7% |
Insulin-requiring Type Ii Diabetes Mellitus |
4.7% |
Product Used For Unknown Indication |
4.7% |
Plasma Cell Myeloma |
4.1% |
Diabetes Mellitus |
2.9% |
Neoplasm Malignant |
2.9% |
Prostate Cancer |
2.3% |
Drug Use For Unknown Indication |
1.8% |
Hypertension |
1.8% |
Immunodeficiency Common Variable |
1.8% |
Lupus Nephritis |
1.8% |
Myelodysplastic Syndrome |
1.8% |
Drug Use For Unknown Indication |
1.2% |
Breast Cancer Metastatic |
1.2% |
Diabetic Retinal Oedema |
1.2% |
Glycosylated Haemoglobin Increased |
1.2% |
Hepatitis C |
1.2% |
Lung Transplant |
1.2% |
|
Weight Decreased |
29.8% |
Vomiting |
14.0% |
Blood Glucose Increased |
12.3% |
Weight Increased |
7.0% |
Pancreatitis |
5.3% |
Bladder Cancer |
3.5% |
Malaise |
2.6% |
Nausea |
2.6% |
Psychotic Disorder |
2.6% |
Syncope |
2.6% |
Blood Glucose Fluctuation |
1.8% |
Drug Effect Decreased |
1.8% |
Dysgeusia |
1.8% |
Feeling Jittery |
1.8% |
Hypoglycaemia |
1.8% |
Nasopharyngitis |
1.8% |
Off Label Use |
1.8% |
Panniculitis |
1.8% |
Pruritus |
1.8% |
Pulmonary Oedema |
1.8% |
|